Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the prostate, lung, colorectal and ovarian cancer screening trial

International Journal of Cancer

Volumn 136, Issue 6, 2015, Pages E654-E664

  Weinstein, Stephanie J ^a   Purdue, Mark P ^a   Smith Warner, Stephanie A ^b   Mondul, Alison M ^a   Black, Amanda ^a   Ahn, Jiyoung ^c   Huang, Wen Yi ^a   Horst, Ronald L ^d   Kopp, William ^e   Rager, Helen ^e   Ziegler, Regina G ^a   Albanes, Demetrius ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Heartland Assays LLC   (United States)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

25 Hydroxyvitamin D; Colorectal cancer; Prospective study; Serum biomarkers; Vitamin D binding protein

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D BINDING PROTEIN; 25-HYDROXYVITAMIN D; VITAMIN D;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SEASONAL VARIATION; SIGMOIDOSCOPY; UNITED STATES; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; MIDDLE AGED; RISK; STATISTICAL MODEL;

AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 84961288230     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29157     Document Type: Article

References (52)

1. IOM (Institute of Medicine). Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press, 2011.
2. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
3. IARC. Vitamin D and cancer. Lyon, France: International Agency for Research on Cancer, 2009.
4. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009;19:73-8.
5. Cooke NE, Haddad JG. Vitamin D binding protein. In: Feldman D, Glorieux FH, Pike JW, eds. Vitamin D. San Diego, CA: Academic Press, 1997. 87-101.
6. Speeckaert M, Huang G, Delanghe JR, et al. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006;372:33-42.
7. Kisker O, Onizuka S, Becker CM, et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003;5:32-40.
8. Gregory KJ, Zhao B, Bielenberg DR, et al. Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One 2010;5:e13428.
9. Weinstein SJ, Stolzenberg-Solomon RZ, Kopp W, et al. Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study. Cancer Res 2012;72:1190-8.
10. Mondul AM, Weinstein SJ, Moy KA, et al. Vitamin D binding protein, circulating vitamin D, and risk of renal cell carcinoma. Int J Cancer 2014;134:2699-706.
11. Weinstein SJ, Mondul AM, Kopp W, et al. Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. Int J Cancer 2013;132:2940-7.
12. Mondul AM, Weinstein SJ, Virtamo J, et al. Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer. Br J Cancer 2012;107:1589-94.
13. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011;128:1414-24.
14. Touvier M, Chan DS, Lau R, et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2011;20:1003-16.
15. Lee JE, Li H, Chan AT, et al. Circulating levels of Vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-analysis of prospective studies. Cancer Prevent Res 2011;4:735-43.
16. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-96.
17. Woolcott CG, Wilkens LR, Nomura AM, et al. Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the Multiethnic Cohort study. Cancer Epidemiol Biomarkers Prev 2010;19:130-4.
18. Jenab M, Bueno-de-Mesquita HB, Ferrari P, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study. Br Med J 2010;340:b5500.
19. Feskanich D, Ma J, Fuchs CS, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004;13:1502-8.
20. Weinstein SJ, Yu K, Horst RL, et al. Serum 25-hydroxyvitamin D and risks of colon and rectal cancer in Finnish men. Am J Epidemiol 2011;173:499-508.
21. Otani T, Iwasaki M, Sasazuki S, et al. Plasma vitamin D and risk of colorectal cancer: the Japan public health center-based prospective study. Br J Cancer 2007;97:446-51.
22. Wu K, Feskanich D, Fuchs CS, et al. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 2007;99:1120-29.
23. Ahn J, Peters U, Albanes D, et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 2008;100:796-804.
24. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012;366:2345-2357.
25. Fleming ID, Cooper JS, Henson ED, et al. AJCC cancer staging manual, 5th edn. Philadelphia, PA: Lippincot-Raven, 1997.
26. Wagner D, Hanwell HE, Vieth R. An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem 2009;42:1549-56.
27. Fears TR, Ziegler RG, Donaldson JL, et al. Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. Cancer Epidemiol Biomarkers Prev 2000;9:403-12.
28. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988;67:373-8.
29. Stolzenberg-Solomon RZ, Hayes RB, Horst RL, et al. Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res 2009;69:1439-47.
30. Looker AC, Pfeiffer CM, Lacher DA, et al. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 2008;88:1519-27.
31. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 2010;172:81-93.
32. Borkowf CB, Albert PS, Abnet CC. Using lowess to remove systematic trends over time in predictor variables prior to logistic regression with quantile categories. Stat Med 2003;22:1477-93.
33. Bouillon R, Van Assche FA, Van Baelen H, et al. Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration. J Clin Invest 1981;67:589-96.
34. Hollis BW, Bikle DD. Vitamin D-binding protein and vitamin D in blacks and whites [letter]. N Engl J Med 2014;370:879-80.
35. Ordonez-Mena JM, Schottker B, Haug U, et al. Serum 25-hydroxyvitamin D and cancer risk in older adults: results from a large German prospective cohort study. Cancer Epidemiol Biomarkers Prev 2013;22:905-16.
36. McCullough ML, Bostick RM, Mayo TL. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 2009;29:111-32.
37. Hiraki LT, Qu C, Hutter CM, et al. Genetic predictors of circulating 25-hydroxyvitamin D and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2013;22:2037-46.
38. Trivedi D, Doll R, Khaw K. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. B Med J 2003;326:469.
39. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586-91.
40. Avenell A, MacLennan GS, Jenkinson DJ, et al. Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial). J Clin Endocrinol Metab 2012;97:614-22.
41. Prentice RL, Pettinger MB, Jackson RD, et al. Health risks and benefits from calcium and vitamin D supplementation: women's health initiative clinical trial and cohort study. Osteoporos Int 2013;24:567-80.
42. Hannan EL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv 2008;1:211-17.
43. Meyer MB, Goetsch PD, Pike JW. VDR/RXR and TCF4/beta-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. Mol Endocrinol 2012;26:37-51.
44. Makishima M, Lu TT, Xie W, et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002;296:1313-16.
45. Moy KA, Mondul AM, Zhang H, et al. Genome-wide association study of circulating vitamin D-binding protein. Am J Clin Nutr 2014;99:1424-31.
46. Rejnmark L, Lauridsen AL, Vestergaard P, et al. Diurnal rhythm of plasma 1,25-dihydroxyvitamin D and vitamin D-binding protein in postmenopausal women: relationship to plasma parathyroid hormone and calcium and phosphate metabolism. Eur J Endocrinol 2002;146:635-42.
47. Bolland MJ, Grey AB, Ames RW, et al. Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein. Clin Endocrinol (Oxf) 2007;67:259-64.
48. Platz EA, Leitzmann MF, Hollis BW, et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004;15:255-65.
49. Hofmann JN, Yu K, Horst RL, et al. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2010;19:927-31.
50. Jorde R, Sneve M, Hutchinson M, et al. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am J Epidemiol 2010;171:903-8.
51. Afzal S, Bojesen SE, Nordestgaard BG. Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. Clin Chem 2013;59:771-80.
52. Sonderman JS, Munro HM, Blot WJ, et al. Reproducibility of serum 25-hydroxyvitamin D and vitamin D-binding protein levels over time in a prospective cohort study of black and white adults. Am J Epidemiol 2012;176:615-21.